natali_mis
Before organic (NASDAQ: BEFORE) The company's shares rose 64% in after-hours trading Thursday after it reported positive data on its gene-edited stem cell therapy, trem-cel, in the treatment of acute myeloid leukemia, or AML.
The phase 1/2 study, called VBP101, is evaluating trem-cel in combination with Pfizer's (PFE) Mylotarg in the treatment of patients with relapsed or refractory acute myeloid leukemia.
VOR (VOR) said in a statement that the study data “demonstrated reliable engraftment, protection against Mylotarg-specific toxicity, an expanded therapeutic window for Mylotarg and early evidence of patient benefit.”
The company intends to approach the FDA to discuss the design of a pivotal trial for the trem-cel plus Mylotarg combination around the end of the year, he added.
Vor (VOR) also announced it was moving forward with studies that would enable Phase 1 testing for another therapy candidate, an antibody-drug conjugate called VADC45.
